Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Colorectal Cancer | Primary research

Integrated characterization and validation of the prognostic significance of microRNA-200s in colorectal cancer

Authors: Qiliang Peng, Ming Cheng, Ting Li, Xiangying Chen, Yi Shen, Yaqun Zhu, Bo Xu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Accumulating evidence has demonstrated that microRNA-200s (miR-200a, miR-200b and miR-200c) could serve as promising molecular biomarkers for cancer prognosis. Nevertheless, the associations between miR-200s expression and colorectal cancer (CRC) prognosis remain controversial.

Methods

We applied two mainstream approaches combining meta-analysis and bioinformatics analysis to answer whether miR-200s were associated with the prognosis of CRC patients and why miR-200s could be used as prognostic biomarkers for CRC.

Results

Consequently, low expression of miR-200s was associated with unfavorable overall survival (OS) in CRC patients (HR: 1.09; 95% CI 1.01–1.17; P = 0.025). According to the subgroup analysis, the prognostic role of miR-200s was more significant for tissue samples, large samples, American patients and miR-200a subgroups. Then the target genes of miR-200s were predicted and applied for functional enrichment analyses. The results showed that the target genes of miR-200s were mainly enriched into some vital ontology subjects such as regulation ability, key cell structures and binding function. Moreover, a series of important signaling pathways were identified, which were significantly linked with the initiation and progression of CRC. Additionally, a protein‑protein interaction (PPI) network of miR-200s targets was constructed to screen hub genes and modules. The identified hub genes and modules were validated to be highly involved in the occurrence and development of CRC.

Conclusions

Current evidences revealed that miR-200s could be promising biomarkers for CRC prognosis. However, the findings still need to be validated with more larger-scale prospective studies and biological experiments before miR-200s could be applied into clinical application.
Appendix
Available only for authorised users
Literature
1.
2.
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.PubMedCrossRef
3.
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80.PubMedCrossRef
4.
5.
6.
7.
8.
Liu W, Zhang K, Wei P, et al. Correlation between miR-200 family overexpression and cancer prognosis. Dis Markers. 2018;2018:6071826.PubMedPubMedCentral
9.
Yu C, Wan H, Shan R, et al. The prognostic value of the MiR-200 family in colorectal cancer: a meta-analysis with 1882 patients. J Cancer. 2019;10(17):4009–16.PubMedPubMedCentralCrossRef
10.
Page MJ, Moher D. Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and extensions: a scoping review. Syst Rev. 2017;6(1):263.PubMedPubMedCentralCrossRef
11.
12.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
13.
14.
Mueller M, D’Addario M, Egger M, et al. Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations. BMC Med Res Methodol. 2018;18(1):44.PubMedPubMedCentralCrossRef
15.
Augusteijn HEM, van Aert RCM, van Assen M. The effect of publication bias on the Q test and assessment of heterogeneity. Psychol Methods. 2019;24(1):116–34.PubMedCrossRef
16.
Hsu SD, Lin FM, Wu WY, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(Database issue):D163–9.PubMedCrossRef
17.
Huang HY, Lin YC, Li J, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 2019;48(D1):D148–54.PubMedCentral
18.
The Gene Ontology C. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330–8.CrossRef
19.
Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019;47(D1):D590–5.PubMedCrossRef
20.
Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3.PubMedCrossRef
21.
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.PubMedCrossRef
22.
Tang Y, Li M, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Bio Syst. 2015;127:67–72.
23.
Diaz T, Tejero R, Moreno I, et al. Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol. 2014;109(7):676–83.PubMedCrossRef
24.
Pichler M, Ress AL, Winter E, et al. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br J Cancer. 2014;110(6):1614–21.PubMedPubMedCentralCrossRef
25.
Slattery ML, Herrick JS, Mullany LE, et al. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer. 2015;137(2):428–38.PubMedCrossRef
26.
Toiyama Y, Hur K, Tanaka K, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259(4):735–43.PubMedCrossRef
27.
28.
Maierthaler M, Benner A, Hoffmeister M, et al. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer. 2017;140(1):176–87.PubMedCrossRef
29.
Roh MS, Lee HW, Jung SB, et al. Expression of miR-200c and its clinicopathological significance in patients with colorectal cancer. Pathol Res Pract. 2018;214(3):350–5.PubMedCrossRef
30.
Santasusagna S, Moreno I, Navarro A, et al. Prognostic impact of miR-200 family members in plasma and exosomes from tumor-draining versus peripheral veins of colon cancer patients. Oncology. 2018;95(5):309–18.PubMedCrossRef
31.
Shelton PM, Duran A, Nakanishi Y, et al. The Secretion of miR-200s by a PKCzeta/ADAR2 signaling axis promotes liver metastasis in colorectal cancer. Cell Rep. 2018;23(4):1178–91.PubMedPubMedCentralCrossRef
32.
Carter JV, O’Brien SJ, Burton JF, et al. The microRNA-200 family acts as an oncogene in colorectal cancer by inhibiting the tumor suppressor RASSF2. Oncol Lett. 2019;18(4):3994–4007.PubMedPubMedCentral
33.
Xi Y, Formentini A, Chien M, et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights. 2006;2:113–21.PubMed
34.
Xu L, Tang L, Zhang L. Proteoglycans as miscommunication biomarkers for cancer diagnosis. Prog Mol Biol Transl Sci. 2019;162:59–92.PubMedCrossRef
35.
36.
Ma J, Matkar S, He X, Hua X. FOXO family in regulating cancer and metabolism. Semin Cancer Biol. 2018;50:32–41.PubMedCrossRef
37.
38.
39.
Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102.PubMedCrossRef
40.
41.
Haseeb M, Pirzada RH, Ain QU, Choi S. Wnt signaling in the regulation of immune cell and cancer therapeutics. Cells. 2019;8(11):1380.PubMedCentralCrossRef
42.
Soleimani A, Rahmani F, Saeedi N, et al. The potential role of regulatory microRNAs of RAS/MAPK signaling pathway in the pathogenesis of colorectal cancer. J Cell Biochem. 2019;120(12):19245–53.PubMedCrossRef
43.
Ciliberto D, Staropoli N, Caglioti F, et al. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: a classic and bayesian meta-analysis. Crit Rev Oncol Hematol. 2018;125:69–77.PubMedCrossRef
44.
Murugan AK. mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92–111.PubMedCrossRef
45.
Pezzuto A, Carico E. Role of HIF-1 in cancer progression: novel insights. A review. Curr Mol Med. 2018;18(6):343–51.PubMedCrossRef
46.
Karagiota A, Kourti M, Simos G, Mylonis I. HIF-1alpha-derived cell-penetrating peptides inhibit ERK-dependent activation of HIF-1 and trigger apoptosis of cancer cells under hypoxia. Cell Mol Life Sci. 2019;76(4):809–25.PubMedCrossRef
47.
Yeung YT, Guerrero-Castilla A, Cano M, Munoz MF, Ayala A, Arguelles S. Dysregulation of the Hippo pathway signaling in aging and cancer. Pharmacol Res. 2019;143:151–65.PubMedCrossRef
48.
Bigas A, Espinosa L. The multiple usages of Notch signaling in development, cell differentiation and cancer. Curr Opin Cell Biol. 2018;55:1–7.CrossRefPubMed
49.
50.
Icard P, Fournel L, Wu Z, Alifano M, Lincet H. Interconnection between metabolism and cell cycle in cancer. Trends Biochem Sci. 2019;44(6):490–501.PubMedCrossRef
51.
Peng Q, Shen Y, Lin K, Zou L, Shen Y, Zhu Y. Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer. J Transl Med. 2018;16(1):127.PubMedPubMedCentralCrossRef
Metadata
Title
Integrated characterization and validation of the prognostic significance of microRNA-200s in colorectal cancer
Authors
Qiliang Peng
Ming Cheng
Ting Li
Xiangying Chen
Yi Shen
Yaqun Zhu
Bo Xu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-1142-1

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Establishment and validation of a novel nomogram incorporating clinicopathological parameters into the TNM staging system to predict prognosis for stage II colorectal cancer

Primary research

Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

Primary research

Integrated nomogram based on five stage-related genes and TNM stage to predict 1-year recurrence in hepatocellular carcinoma

Primary research

Circular RNA ATXN7 promotes the development of gastric cancer through sponging miR-4319 and regulating ENTPD4

Primary research

High expression of ESRP1 regulated by circ-0005585 promotes cell colonization in ovarian cancer

Primary research

Silencing of microRNA-517a induces oxidative stress injury in melanoma cells via inactivation of the JNK signaling pathway by upregulating CDKN1C
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits